memantine has been researched along with Anxiety in 22 studies
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several studies have reported on the beneficial effects of memantine on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease." | 7.91 | Memantine ameliorates learning and memory disturbance and the behavioral and psychological symptoms of dementia in thiamine-deficient mice. ( Kashimoto, Y; Kitano, Y; Makino, M; Murasawa, H; Pawlak, A; Takahashi-Ito, K, 2019) |
| "Chronic amphetamine use results in anxiety-like states after drug cessation." | 7.79 | The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013) |
| "Several studies have reported on the beneficial effects of memantine on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease." | 3.91 | Memantine ameliorates learning and memory disturbance and the behavioral and psychological symptoms of dementia in thiamine-deficient mice. ( Kashimoto, Y; Kitano, Y; Makino, M; Murasawa, H; Pawlak, A; Takahashi-Ito, K, 2019) |
| "Chronic amphetamine use results in anxiety-like states after drug cessation." | 3.79 | The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013) |
| "Microinjections of glutamic acid, serotonin, and sulpiride in the ventromedial hypothalamus reduced anxiety in an illuminated platform avoidance task in rats, while dopamine, apomorphine, picrotoxin, and memantine increased it." | 3.71 | The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats. ( Gordienko, DV; Krivobok, GK; Pankrat'ev, DV; Talalaenko, AN; Zinkovich, II, 2001) |
| " Safety and tolerability were assessed by the number of withdrawals, adverse events (AEs) and monitoring of vital signs." | 2.73 | Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. ( Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007) |
| "Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist currently used for moderate-to-severe Alzheimer's disease." | 1.56 | Memantine misuse and social networks: A content analysis of Internet self-reports. ( Michel, B; Natter, J, 2020) |
| "Post-traumatic stress disorder (PTSD) is a psychiatric disorder associated with memories of traumatic experiences." | 1.51 | Improvement of PTSD-like behavior by the forgetting effect of hippocampal neurogenesis enhancer memantine in a social defeat stress paradigm. ( Furuyashiki, T; Ishikawa, R; Kida, S; Kitaoka, S; Uchida, C, 2019) |
| "Memantine is an uncompetitive N-methyl D-aspartate glutamatergic receptors antagonist and has shown beneficial effect on cognitive function especially in Alzheimer's disease." | 1.42 | Modification of hippocampal markers of synaptic plasticity by memantine in animal models of acute and repeated restraint stress: implications for memory and behavior. ( Ali, MM; Amin, SN; Attia, YM; El-Aidi, AA; Rashed, LA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Sahraei, M | 1 |
| Sahraei, H | 1 |
| Rahimi, M | 1 |
| Khosravi, M | 1 |
| Ganjkhani, M | 1 |
| Meftahi, GH | 1 |
| Abdo Qaid, EY | 1 |
| Abdullah, Z | 1 |
| Zakaria, R | 1 |
| Long, I | 1 |
| Siao, WH | 1 |
| Chang, FY | 1 |
| Chen, YC | 1 |
| Toccaceli Blasi, M | 1 |
| Valletta, M | 1 |
| Trebbastoni, A | 1 |
| D'Antonio, F | 1 |
| Talarico, G | 1 |
| Campanelli, A | 1 |
| Sepe Monti, M | 1 |
| Salati, E | 1 |
| Gasparini, M | 1 |
| Buscarnera, S | 1 |
| Salzillo, M | 1 |
| Canevelli, M | 1 |
| Bruno, G | 1 |
| Natter, J | 1 |
| Michel, B | 1 |
| Stazi, M | 1 |
| Wirths, O | 1 |
| Zahra, A | 1 |
| Jiang, J | 1 |
| Chen, Y | 1 |
| Long, C | 1 |
| Yang, L | 1 |
| Yuanyuan, J | 1 |
| Junyan, Z | 1 |
| Cuola, D | 1 |
| Jingjing, C | 1 |
| Yuhui, S | 1 |
| Dan, X | 1 |
| Wei, D | 1 |
| Yongsheng, Z | 1 |
| Makino, M | 1 |
| Takahashi-Ito, K | 1 |
| Murasawa, H | 1 |
| Pawlak, A | 1 |
| Kashimoto, Y | 1 |
| Kitano, Y | 1 |
| Ishikawa, R | 1 |
| Uchida, C | 1 |
| Kitaoka, S | 1 |
| Furuyashiki, T | 1 |
| Kida, S | 1 |
| Koltunowska, D | 1 |
| Gibula-Bruzda, E | 1 |
| Kotlinska, JH | 1 |
| Vignisse, J | 1 |
| Steinbusch, HW | 1 |
| Grigoriev, V | 1 |
| Bolkunov, A | 1 |
| Proshin, A | 1 |
| Bettendorff, L | 1 |
| Bachurin, S | 1 |
| Strekalova, T | 1 |
| Amin, SN | 1 |
| El-Aidi, AA | 1 |
| Ali, MM | 1 |
| Attia, YM | 1 |
| Rashed, LA | 1 |
| Kirby, T | 1 |
| Kotlinska, J | 1 |
| Bochenski, M | 1 |
| Hogan, DB | 1 |
| Bailey, P | 1 |
| Black, S | 1 |
| Carswell, A | 1 |
| Chertkow, H | 1 |
| Clarke, B | 1 |
| Cohen, C | 1 |
| Fisk, JD | 1 |
| Forbes, D | 1 |
| Man-Son-Hing, M | 1 |
| Lanctôt, K | 1 |
| Morgan, D | 1 |
| Thorpe, L | 1 |
| Clerici, F | 1 |
| Vanacore, N | 1 |
| Elia, A | 1 |
| Spila-Alegiani, S | 1 |
| Pomati, S | 1 |
| Da Cas, R | 1 |
| Raschetti, R | 1 |
| Mariani, C | 1 |
| Talalaenko, AN | 2 |
| Pankrat'ev, DV | 2 |
| Goncharenko, NV | 1 |
| Danysz, W | 1 |
| Jones, RW | 1 |
| Bayer, A | 1 |
| Inglis, F | 1 |
| Barker, A | 1 |
| Phul, R | 1 |
| Zdanys, K | 1 |
| Tampi, RR | 1 |
| Gordienko, DV | 1 |
| Zinkovich, II | 1 |
| Krivobok, GK | 1 |
2 reviews available for memantine and Anxiety
| Article | Year |
|---|---|
Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.
Topics: Anxiety; Cholinesterase Inhibitors; Dementia; Dependency, Psychological; Depression; Dopamine Agents | 2008 |
A systematic review of off-label uses of memantine for psychiatric disorders.
Topics: Anxiety; Bipolar Disorder; Bulimia Nervosa; Child; Child Development Disorders, Pervasive; Depressio | 2008 |
1 trial available for memantine and Anxiety
| Article | Year |
|---|---|
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Dopamine Agents; Double-Blind Method; Drug Admi | 2007 |
19 other studies available for memantine and Anxiety
| Article | Year |
|---|---|
Anxiogenic and anxiolytic effects of memantine injected into the ventral hippocampus in male stressed mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Hippocampus; Male; Memantine; Mice; N-Methy | 2022 |
Minocycline Attenuates Lipopolysaccharide-Induced Locomotor Deficit and Anxiety-like Behavior and Related Expression of the BDNF/CREB Protein in the Rat Medial Prefrontal Cortex (mPFC).
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Ga | 2022 |
Memantine treats psychosis and agitation associated with Moderna COVID-19 vaccine.
Topics: 2019-nCoV Vaccine mRNA-1273; Anxiety; COVID-19; Humans; Memantine; Psychotic Disorders | 2023 |
Sundowning in Patients with Dementia: Identification, Prevalence, and Clinical Correlates.
Topics: Alzheimer Disease; Anxiety; Delirium; Dementia; Humans; Memantine; Prevalence | 2023 |
Memantine misuse and social networks: A content analysis of Internet self-reports.
Topics: Anxiety; Attention Deficit Disorder with Hyperactivity; Depression; Humans; Internet; Memantine; Obs | 2020 |
Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer's Disease.
Topics: Administration, Oral; Alzheimer Disease; Animals; Anxiety; Behavior, Animal; CA1 Region, Hippocampal | 2021 |
Memantine rescues prenatal citalopram exposure-induced striatal and social abnormalities in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Corpus Striatum; Excitatory | 2018 |
Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway.
Topics: Alcoholism; Animals; Anxiety; Anxiety Disorders; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2018 |
Memantine ameliorates learning and memory disturbance and the behavioral and psychological symptoms of dementia in thiamine-deficient mice.
Topics: Administration, Oral; Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Body Weight; Dementia | 2019 |
Improvement of PTSD-like behavior by the forgetting effect of hippocampal neurogenesis enhancer memantine in a social defeat stress paradigm.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Hippocampus; Male; Memantine; Memory; Mice, | 2019 |
The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
Topics: Acamprosate; Amphetamine; Animals; Anxiety; Bridged Bicyclo Compounds; Dose-Response Relationship, D | 2013 |
Concomitant manipulation of murine NMDA- and AMPA-receptors to produce pro-cognitive drug effects in mice.
Topics: Allyl Compounds; Animals; Anxiety; Avoidance Learning; Brain; Conditioning, Psychological; Dose-Resp | 2014 |
Modification of hippocampal markers of synaptic plasticity by memantine in animal models of acute and repeated restraint stress: implications for memory and behavior.
Topics: Acute Disease; Animals; Anxiety; Behavior, Animal; Biomarkers; Brain-Derived Neurotrophic Factor; Ca | 2015 |
Anxious wait for patients and big pharma.
Topics: Anxiety; Drug Industry; Humans; Jurisprudence; Memantine; New York City; Patents as Topic; Time Fact | 2015 |
The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Behavior, Animal; Central Nervous System Depressa | 2008 |
Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Apathy; Depression; Dopamine Agents; Feeding Be | 2012 |
Neurochemical characteristics of the ventromedial hypothalamus in mediating the antiaversive effects of anxiolytics in different models of anxiety.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Anti- | 2003 |
Society of neuroscience-33rd annual meeting: metabotropic glutamate receptors.
Topics: Animals; Antiparkinson Agents; Anxiety; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Hunting | 2004 |
The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats.
Topics: Adrenergic Agents; Animals; Anxiety; Apomorphine; Avoidance Learning; Disease Models, Animal; Dopami | 2001 |